Fungal cell wall septation and cytokinesis are inhibited by bleomycins

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 10, 2003, Pages 3281-3289

  Moore, Carol W ^a   McKoy, Judith ^a   Del Valle, Robert ^a   Armstrong, Donald ^b   Bernard, Edward M ^b   Katz, Norman ^c   Gordon, Ronald E ^c  

^a CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BLEOMYCIN A2; BLEOMYCIN B2;

ARTICLE; ASPERGILLUS FUMIGATUS; CELL DIVISION; CELL WALL; CONIDIUM; CRYPTOCOCCUS NEOFORMANS; CULTURE MEDIUM; CYTOKINESIS; CYTOLOGY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ELECTRON MICROSCOPY; FUNGAL CELL; FUNGICIDAL ACTIVITY; FUNGUS; FUNGUS GROWTH; FUNGUS HYPHAE; GROWTH INHIBITION; HUMAN; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

ASPERGILLUS FUMIGATUS; BLEOMYCIN; CELL DIVISION; CELL WALL; CRYPTOCOCCUS NEOFORMANS; FUNGI; HUMANS; MICROSCOPY, ELECTRON; MICROSCOPY, ELECTRON, SCANNING; SACCHAROMYCES CEREVISIAE;

EID: 0141890252     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.10.3281-3289.2003     Document Type: Article

References (62)

1. Armstrong, D. 1989. Problems in management of opportunistic fungal diseases. Rev. Infect. Dis. 11(Suppl. 7):S1591-S1599.
2. Beaudouin, R., S. T. Lim, J. A. Steide, M. Powell, J. McKoy, A. J. Pramanik, E. Johnson, C. W. Moore, and P. N. Lipke. 1993. Bleomycin affects cell wall anchorage of mannoproteins in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 37:1264-1269.
3. Cabib, E., D. H. Roh, M. Schmidt, L. B. Crotti, and A. Varma. 2001. The yeast cell wall and septum as paradigms of cell growth and morphogenesis. J. Biol. Chem. 276:19679-19682.
4. Clemons, K. V., J. H. McCusker, K. Davis, and D. A. Stevens. 1994. Comparative pathogenesis of clinical and nonclinical isolates of Saccharomyces cerevisiae. J. Infect. Dis. 169:859-867.
5. Crooke, S. T., and W. T. Bradner. 1976. Bleomycin, a review. J. Med. 7:333-428.
6. de Nobel, H., E. H. van Den, and F. M. Klis. 2000. Cell wall maintenance in fungi. Trends Microbiol. 8:344-345.
7. Diamond, R. D. 1988. Fungal surfaces: effects of interactions with phagocytic cells. Rev. Infect. Dis. 10(Suppl. 2):S428-S431.
8. Dupont, B., M. Richardson, P. E. Verweij, and J. F. Meis. 2000. Invasive aspergillosis. Med. Mycol. 38(Suppl. 1):215-224.
9. Espinel-Ingroff, A., K. Dawson, M. Pfaller, E. Anaissie, B. Breslin, D. Dixon, A. Fothergill, V. Paetznick, J. Peter, and M. Rinaldi. 1995. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob. Agents Chemother. 39:314-319.
10. Fernandez, C. O., N. C. Fernandez, A. Ariosa, and N. J. Fernandez. 2003. Characterization of a group of patients with cryptococcosis of the central nervous system. Rev. Neurol. 36:316-321.
11. Giri, S. N., R. Blaisdell, R. B. Rucker, Q. Wang, and D. M. Hyde. 1994. Amelioration of bleomycin-induced lung fibrosis in hamsters by dietary supplementation with taurine and niacin: biochemical mechanisms. Environ. Health Perspect. 102(Suppl. 10):137-147.
12. Goldstein, A. L., and J. H. McCusker. 2001. Development of Saccharomyces cerevisiae as a model pathogen. A system for the genetic identification of gene products required for survival in the mammalian host environment. Genetics 159:499-513.
13. Gordon, R. E., R. F. Heller, and R. F. Heller. 1992. Taurine protection of lungs in hamster models of oxidant injury: a morphologic time study of paraquat and bleomycin treatment. Adv. Exp. Med. Biol. 315:319-328.
14. Gottfredsson, M., and J. R. Perfect. 2000. Fungal meningitis. Semin. Neurol. 20:307-322.
15. Hazen, K. C. 1995. New and emerging yeast pathogens. Clin. Microbiol. Rev. 8:462-478.
16. Hogan, L. H., B. S. Klein, and S. M. Levitz. 1996. Virulence factors of medically important fungi. Clin. Microbiol. Rev. 9:469-488.
17. Holzheimer, R. G., and H. Dralle. 2002. Management of mycoses in surgical patients - review of the literature. Eur. J. Med. Res. 7:200-226.
18. Kurokawa, C. S., M. F. Sugizaki, and M. T. Peracoli. 1998. Virulence factors in fungi of systemic mycoses. Rev. Inst. Med. Trop. Sao Paulo 40:125-135.
19. Kwon-Chung, K. J., T. C. Sorrell, F. Dromer, E. Fung, and S. M. Levitz. 2000. Cryptococcosis: clinical and biological aspects. Med. Mycol. 38(Suppl. 1):205-213.
20. Latge, J. P. 1999. Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12:310-350.
21. Latge, J. P., J. P. Debeaupuis, J. Sarfati, M. Diaquin, and S. Paris. 1993. Cell wall antigens in Aspergillus fumigatus. Arch. Med. Res. 24:269-274.
22. Lazo, J. S. 1999. Bleomycin. Cancer Chemother. Biol. Response Modif. 18:39-45.
23. Lim, S. T., C. K. Jue, C. W. Moore, and P. N. Lipke. 1995. Oxidative cell wall damage mediated by bleomycin-Fe(II) in Saccharomyces cerevisiae. J. Bacteriol. 177:3534-3539.
24. Lipke, P. N., and R. Ovalle. 1998. Cell wall architecture in yeast: new structure and new challenges. J. Bacteriol. 180:3735-3740.
25. Loeffler, J., and D. A. Stevens. 2003. Antifungal drug resistance. Clin. Infect. Dis. 36:S31-S41.
26. Mamidi, A., J. A. DeSimone, and R. J. Pomerantz. 2002. Central nervous system infections in individuals with HIV-1 infection. J. Neurovirol. 8:158-167.
27. Marshall, R. P., R. J. McAnulty, and G. J. Laurent. 1997. The pathogenesis of pulmonary fibrosis: is there a fibrosis gene? Int. J. Biochem. Cell Biol. 29:107-120.
28. Masia, C. M., and R. F. Gutierrez. 2002. Antifungal drug resistance to azoles and polyenes. Lancet Infect. Dis. 2:550-563.
29. McCusker, J. H., K. V. Clemons, D. A. Stevens, and R. W. Davis. 1994. Genetic characterization of pathogenic Saccharomyces cerevisiae isolates. Genetics 136:1261-1269.
30. McCusker, J. H., K. V. Clemons, D. A. Stevens, and R. W. Davis. 1994. Saccharomyces cerevisiae virulence phenotype as determined with CD-1 mice is associated with the ability to grow at 42 degrees C and form pseudohyphae. Infect. Immun. 62:5447-5455.
31. Moore, C. W. 1982. Ligase-deficient yeast cells exhibit defective DNA rejoining and enhanced gamma ray sensitivity. J. Bacteriol. 150:1227-1233.
32. Moore, C. W. 1982. Modulation of bleomycin cytotoxicity. Antimicrob. Agents Chemother. 21:595-600.
33. 2 in the absence of DNA repair. Biochemistry 29:1342-1347.
34. Moore, C. W. 1999. Bleomycin, p. 292-297. In T. Creighton (ed.), Encyclopedia of molecular biology. John Wiley and Sons, Inc., New York, N.Y.
35. 2 on Saccharomyces cerevisiae cell walls and membranes. Antimicrob. Agents Chemother. 36:2497-2505.
36. Moore, C. W., J. McKoy, M. Dardalhon, D. Davermann, M. Martinez, and D. Averbeck. 2000. DNA damage-inducible and RAD52-independent repair of DNA double-strand breaks in Saccharomyces cerevisiae. Genetics 154: 1085-1099.
37. Moore, C. W., and A. Schmick. 1979. Recombinogenicity and mutagenicity of saccharin in Saccharomyces cerevisiae. Mutat. Res. 67:215-219.
38. Murphy, A. R., and K. A. Kavanagh. 2001. Adherence of clinical isolates of Saccharomyces cerevisiae to buccal epithelial cells. Med. Mycol. 39:123-127.
39. Murphy, M., E. M. Bernard, T. Ishimaru, and D. Armstrong. 1997. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 41:696-698.
40. Ovalle, R., S. T. Lim, B. Holder, C. K. Jue, C. W. Moore, and P. N. Lipke. 1998. A spheroplast rate assay for determination of cell wall integrity in yeast. Yeast 14:1159-1166.
41. Perfect, J. R., and A. Casadevall. 2002. Cryptococcosis. Infect. Dis. Clin. North Am. 16:837-874.
42. Ponton, J., R. Ruchel, K. V. Clemons, D. C. Coleman, R. Grillot, J. Guarro, D. Aldebert, P. Ambroise-Thomas, J. Cano, A. J. Carrillo-Munoz, J. Gene, C. Pinel, D. A. Stevens, and D. J. Sullivan. 2000. Emerging pathogens. Med. Mycol. 38(Suppl. 1):225-236.
43. Powderly, W. G. 2000. Cryptococcal meningitis in HIV-infected patients. Curr. Infect. Dis. Rep. 2:352-357.
44. Reiss, E., V. M. Hearn, D. Poulain, and M. G. Shepherd. 1992. Structure and function of the fungal cell wall. J. Med. Vet. Mycol. 30(Suppl. 1):143-156.
45. Rippon, J. W. 1988. Medical mycology. W. B. Saunders Company, Philadelphia, Pa.
46. Ruiz-Herrera, J. 1992. Fungal cell wall: structure, synthesis and assembly. CRC Press, Boca Raton, Fla.
47. Saint Georgiev, V. 2000. Membrane transporters and antifungal drug resistance. Curr. Drug Targets 1:261-284.
48. Sanglard, D. 2002. Clinical relevance of mechanisms of antifungal drug resistance in yeasts. Enferm. Infecc. Microbiol. Clin. 20:462-469.
49. Sanglard, D., and F. C. Odds. 2002. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. 2:73-85.
50. Schmitt, H. J., E. M. Bernard, J. Andrade, F. Edwards, B. Schmitt, and D. Armstrong. 1988. MIC and fungicidal activity of terbinafine against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. 32:780-781.
51. Schmitt, H. J., F. Edwards, J. Andrade, Y. Niki, and D. Armstrong. 1992. Comparison of azoles against aspergilli in vitro and in an experimental model of pulmonary aspergillosis. Chemotherapy 38:118-126.
52. Sepkowitz, K. A. 2002. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin. Infect. Dis. 34:1098-1107.
53. Sleijfer, S. 2001. Bleomycin-induced pneumonitis. Chest 120:617-624.
54. Smits, G. J., J. C. Kapteyn, E. H. van Den, and F. M. Klis. 1999. Cell wall dynamics in yeast. Curr. Opin. Microbiol. 2:348-352.
55. Sudoh, M., T. Yamazaki, K. Masubuchi, M. Taniguchi, N. Shimma, M. Arisawa, and H. Yamada-Okabe. 2000. Identification of a novel inhibitor specific to the fungal chitin synthase. Inhibition of chitin synthase 1 arrests the cell growth, but inhibition of chitin synthase 1 and 2 is lethal in the pathogenic fungus Candida albicans. J. Biol. Chem. 275:32901-32905.
56. Thomas, I., and R. A. Schwartz. 2001. Cutaneous manifestations of systemic cryptococcosis in immunosupressed patients. J. Med. 32:259-266.
57. Umezawa, H. 1976. Structure and action of bleomycin. Prog. Biochem. Pharmacol. 11:18-27.
58. Umezawa, H., K. Maeda, T. Takeuchi, and Y. Okami. 1966. New antibiotics, bleomycin A and B. J. Antibiot. (Tokyo) 19:200-209.
59. Vilchez, R. A., J. Fung, and S. Kusne. 2002. Cryptococcosis in organ transplant recipients: an overview. Am. J. Transplant. 2:575-580.
60. Walsh, T. J., M. A. Viviani, E. Arathoon, C. Chiou, M. Ghannoum, A. H. Groll, and F. C. Odds. 2000. New targets and delivery systems for antifungal therapy. Med. Mycol. 38(Suppl. 1):335-347.
61. Wheat, L. J., M. Goldman, and G. Sarosi. 2002. State-of-the-art review of pulmonary fungal infections. Semin. Respir. Infect. 17:158-181.
62. White, M. H., and D. Armstrong. 1994. Cryptococcosis. Infect. Dis. Clin. North Am. 8:383-398.